驱虫斑鸠菊对淋巴细胞亚类的影响

探讨驱虫斑鸠菊注射液对小鼠免疫功能的影响,揭示其免疫作用机理。采用流式细胞技术测定驱虫斑鸠菊注射液对小鼠脾脏淋巴细胞亚类表达的影响。结果表明,驱虫斑鸠菊可以增强CD4、CD8、CD3T细胞分化抗原的表达,抑制CD19 B细胞分化抗原的表达;说明驱虫斑鸠菊可增强细胞免疫功能、抑制体液免疫功能。     

驱虫斑鸠菊对人黑素瘤细胞增殖酪氨酸酶及黑素生成影响的研究

探讨驱虫斑鸠菊对A375人黑素瘤细胞株细胞增殖、黑素合成以及细胞内酪氨酸酶的作用。四甲基偶氮唑蓝（MTT）比色法测定药物对细胞增殖的影响;采用酶学方法研究药物对酪氨酸酶活性的影响;475nm比色法测定黑素含量。结果表明驱虫斑鸠菊可以增强A375人黑素瘤细胞增殖,提高酪氨酸酶和黑色素合成能力。说明驱虫斑鸠菊治疗白癜风是通过增强酪氨酸酶活性及促进黑素合成而发挥作用的。     

驱虫斑鸠菊对B-16黑素瘤细胞酪氨酸酶活性及黑素生成影响

目的 :探讨驱虫斑鸠菊体外对酪氨酸酶活性影响 ,以及对小鼠B - 16黑素瘤细胞株细胞增殖、黑素合成以及细胞内酪氨酸酶的作用。方法 :利用四甲基偶氮唑蓝 (MTT)比色法测定药物对细胞增殖的影响 ;采用酶学方法研究药物对酪氨酸酶活性的影响 ;470nm比色法测定黑素含量。结果驱虫斑鸠菊体外可激活酪氨酸酶活性 ,增强B - 16鼠黑素瘤细胞增殖 ,提高酪氨酸酶和黑色素合成能力 ;对整体动物黑素细胞具有促进合成和分泌作用。结论在白癜风的治疗中 ,驱虫斑鸠菊可增强酪氨酸酶活性 ,进而促进黑素合成     

驱虫斑鸠菊对小鼠免疫分子的影响

探讨驱虫斑鸠菊对小鼠免疫功能的影响,揭示其免疫作用机理。利用[^3H]-TdR参入法测定驱虫斑鸠菊对小鼠体内免疫功能的影响,运用酶联免疫吸附实验测定驱虫斑鸠菊对小鼠B淋巴细胞分泌抗体功能的影响;采用流式细胞测定方法测定CD19B细胞亚类表达水平;采用[^3H]-TdR参入法利用CTLL－2细胞株测定T淋巴细胞分泌IL－2活性。结果驱虫斑鸠菊的低、中、高三个剂量对体内T、B淋巴细胞的增殖活性、血清总抗体和抗原特异性抗体含量、CD19B细胞亚类表达均有明显的抑制作用,对T淋巴细胞分泌IL－2活性也具有明显抑制作用。说明驱虫斑鸠菊对机体体液免疫和细胞免疫功能都具有明显抑制作用。     

CpG ODN对呼吸道合胞病毒诱导的哮喘小鼠动物模型的免疫治疗作用

目的　探讨Cp G ODN对呼吸道合胞病毒诱导的哮喘小鼠动物模型的免疫治疗作用。方法　用紫外线灭活的呼吸道合胞病毒致敏30只BAL B/ c小鼠后,分别注射生理盐水、地塞米松和Cp G ODN,流式细胞仪检测小鼠的外周血T淋巴细胞亚群,EL ISA法检测小鼠的外周血IL - 4、IFN-γ和总Ig E的含量,并观察肺组织病理变化。结果　Cp G组CD4 +T细胞所占百分比为( 6 9.35±6 .15 ) % ,CD4 +/ CD8+的比值为2 .92±0 .35 ,与哮喘模型组相比显著降低( P<0 .0 5 )。Cp G组IL- 4的含量为( 88.96±9.89) pg/ ml,与哮喘模型组相比明显降低( P<0 .0 5 ) ;IFN-γ的含量为( 4 6 .83±8.84 ) pg/ ml,与哮喘模型组相比显著上升( P<0 .0 5 ) ;总Ig E的含量为( 3.72±0 .6 7) IU/ml,与哮喘模型组相比明显降低( P<0 .0 5 )。肺组织炎症反应明显减轻。结论　Cp G ODN对用紫外线灭活的呼吸道合胞病毒诱导的哮喘小鼠动物模型具有较好的免疫治疗作用     

Mechanism of action of 4‐substituted phenols to induce vitiligo and antimelanoma immunity

Monobenzone is a 4‐substituted phenol that can induce vitiligo and antimelanoma immunity. We investigated the influence of the chemical structure on the biological activity of a series of structurally related 4‐substituted phenols. All phenols inhibited cellular melanin synthesis, and eight of ten phenols inhibited tyrosinase activity, using the MBTH assay. These phenols also induced glutathione (GSH) depletion, indicative of quinone formation and protein thiol binding, which can increase the immunogenicity of melanosomal proteins. Specific T‐cell activation was found upon stimulation with phenol‐exposed pigmented cells, which also reacted with unexposed cells. In contrast, 4‐tertbutylphenol induced immune activation was not restricted to pigment cells, analogous to contact sensitization. We conclude that 4‐substituted phenols can induce specific T‐cell responses against melanocytes and melanoma cells, also acting at distant, unexposed body sites, and may confer a risk of chemical vitiligo. Conversely, these phenols may be applicable to induce specific antimelanoma immunity.     

Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo

Auto-reactive cytotoxic T lymphocytes play a key role in the progressive loss or destruction of melanocytes in vitiligo but the mechanism underlying the loss of self-tolerance is unknown. A deregulation of regulatory T-cell biology has recently been suggested. The analysis of the suppressive effects of peripheral T regulatory cells in vitiligo patients revealed a functional defect in seven of 15 cases. This defect was strongly correlated with disease activity. The evaluation of the percentage of peripheral regulatory T lymphocytes did not reveal any intrinsic quantitative defect. Yet, a decrease in the percentage of such cells was noted in patients with progressive forms, suggesting a recruitment of regulatory T cells from the peripheral blood to the site of injury. This was further corroborated by the significant increase of Forkhead box P3 expression in the vitiliginous skin of patients. Our data support the involvement of a functional defect of peripheral regulatory T cells in the pathogenesis of vitiligo and open new possibilities to advance therapeutic approaches.     

In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial

In this study, we developed an in vivo vitiligo induction model to explore the underlying mechanisms leading to Koebner's phenomenon and to evaluate the efficacy of therapeutic strategies. The model consisted of 12 pigmented test regions on the back of generalized vitiligo patients that were exposed to three Koebner induction methods: cryotherapy, 755 nm laser therapy, and epidermal abrasion. In addition, four cream treatments (pimecrolimus, tacrolimus, steroid and placebo) were randomly applied. Koebnerization was efficiently induced by all three induction methods. In general, cryotherapy was the best method of Koebner induction, followed by 755 nm laser therapy and epidermal abrasion. Reproducible results were obtained, which showed enhanced depigmented surface areas and higher amounts of T lymphocytes in placebo-treated test zones compared to active treated areas. Tacrolimus and local steroids were better inhibitors of Koebner's process (P < 0.05) compared to pimecrolimus. Our in vivo vitiligo induction model is very informative to investigate vitiligo induction and to determine the efficacy of topical treatments in vitiligo. This proof of concept confirms the efficient comparison of head-to-head therapeutic strategies intra-individually in a standardized, specific and better timed way.     

Update on skin repigmentation therapies in vitiligo

Treatment for vitiligo is difficult and prolonged. Nevertheless, at present considerable knowledge accumulated during several decades on the pathogenic mechanisms, revealed important clues for designing new strategies to improve vitiligo depigmentation. With available medical therapies, high repigmentation percentages mostly on facial and neck lesions are achieved, although they are less effective on trunk and limbs and poor on the acral parts of the extremities. Narrow band UVB and psoralens and UVA are the two most important treatments for generalized vitiligo affecting more than 10–20% of the cutaneous surface, and topical corticosteroids, or calcineurin inhibitors are the most valuable treatments for localized vitiligo. Persistence of achieved regimentation is variable and an undefined percentage of patients may have variable recurrence. When vitiligo becomes refractory, surgical methods may improve depigmentation as effectively as with medical therapy; in segmental (unilateral) or long standing, non‐segmental (bilateral) stable vitiligo, repigmentation with surgical methods is usually permanent.     

Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress

Inducible HSP70 (HSP70i) chaperones peptides from stressed cells, protecting them from apoptosis. Upon extracellular release, HSP70i serves an adjuvant function, enhancing immune responses to bound peptides. We questioned whether HSP70i differentially protects control and vitiligo melanocytes from stress and subsequent immune responses. We compared expression of HSP70i in skin samples, evaluated the viability of primary vitiligo and control melanocytes exposed to bleaching phenols, and measured secreted HSP70i. We determined whether HSP70i traffics to melanosomes to contact immunogenic proteins by cell fractionation, western blotting, electron microscopy, and confocal microscopy. Viability of vitiligo and control melanocytes was equally affected under stress. However, vitiligo melanocytes secreted increased amounts of HSP70i in response to MBEH, corroborating with aberrant HSP70i expression in patient skin. Intracellular HSP70i colocalized with melanosomes, and more so in response to MBEH in vitiligo melanocytes. Thus, whereas either agent is cytotoxic to melanocytes, MBEH preferentially induces immune responses to melanocytes.     

Development and validation of the K‐VSCOR for scoring Koebner's phenomenon in vitiligo/non‐segmental vitiligo

The relation of vitiligo/non‐segmental vitiligo (NSV) to Koebner's phenomenon is variably appreciated. Our objective was to develop and validate a simple clinical score for Koebner's phenomenon (KP) in patients with vitiligo/NSV. The study population was composed of 351 individuals in the development sample and 285 patients in the validation sample. Seven variables were independently associated with the presence of KP: disease duration of more than 3 yr, forehead + scalp areas, eyelids, wrists, genital + belt areas, knees and tibial crests. The score computed by the weighted sum of the rounded coefficients of these seven variables ranged from 0 to 56 (mean 38.39 ± 22.93). The probability of having KP was computed as follows: exp (?2.37 + 0.1*score)/exp [1 + (?2.37 + 0.1*score)]. When applying the score to each patient in the validation and the development sample, the score maintained adequate discrimination and calibration (AUC‐ROC = 0.78), arguing that KP can be adequately predicted using our score. Further studies should evaluate KP assessed by the K‐VSCOR in clinical practice with the aim to determine its association with clinical profile, course and treatment response of vitiligo.